Goldman Sachs Group Inc Gt Biopharma, Inc. Transaction History

Goldman Sachs Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.28 $2,737 - $3,484	12,443 Added 119.37%	22,867 $5,000
Q3 2023 May 14, 2024	SELL	$0.24 - $0.35 $2,986 - $4,355	-12,443 Reduced 54.41%	10,424 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $18 - $26	-76 Reduced 0.72%	10,424 $2,000
Q2 2023 May 14, 2024	SELL	$0.22 - $0.55 $1 - $3	-7 Reduced 0.07%	10,500 $3,000
Q2 2023 Aug 14, 2023	SELL	$0.22 - $0.55 $1 - $3	-7 Reduced 0.07%	10,500 $3,000
Q1 2023 May 14, 2024	SELL	$0.46 - $1.05 $17 - $39	-38 Reduced 0.36%	10,507 $5,000
Q1 2023 May 11, 2023	SELL	$0.46 - $1.05 $17 - $39	-38 Reduced 0.36%	10,507 $5,000
Q4 2022 May 14, 2024	SELL	$0.89 - $58.2 $12,895 - $843,259	-14,489 Reduced 57.88%	10,545 $9,000
Q4 2022 Feb 13, 2023	SELL	$0.89 - $58.2 $12,895 - $843,259	-14,489 Reduced 57.88%	10,545 $9,000
Q3 2022 May 14, 2024	BUY	$1.81 - $56.1 $26,031 - $806,830	14,382 Added 135.02%	25,034 $44,000
Q3 2022 Nov 10, 2022	BUY	$1.81 - $56.1 $26,031 - $806,830	14,382 Added 135.02%	25,034 $0
Q2 2022 May 14, 2024	SELL	$1.64 - $3.11 $20,032 - $37,988	-12,215 Reduced 53.42%	10,652 $32,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $41 - $77	-25 Reduced 0.23%	10,652 $32,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $157,448 - $199,838	-60,557 Reduced 85.01%	10,677 $31,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $57,364 - $133,160	18,808 Added 35.88%	71,234 $217,000
Q3 2021 Nov 10, 2021	BUY	$6.68 - $15.26 $350,205 - $800,020	52,426 New	52,426 $353,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.